Boulder, Colo.-based startup Arpeggio Biosciences Inc. scooped up $3.2 million in seed funding in a round led by Khosla Ventures, with participation by Fundersclub, Fifty Years, TechU and Y Combinator.
Frazier Healthcare Partners closed Frazier Life Sciences X LP, the company’s third fund, by exceeding its target with more than $617 million in capital commitments in an oversubscribed fundraiser.
Albuquerque, N.M.-based Agilvax Inc. CEO Joseph Patti told BioWorld that his firm’s antibody-drug conjugate (ADC) method uses “the same linkers, same payloads” as other firms but the “unique factor for us is the target we’re going after” – SLC7A11 (xCT), an amino acid transporter implicated in the metabolic redox activities of metastatic cancer cells.
PERTH, Australia – Sydney-based Noxopharm Ltd. announced that its spin-off, Nyrada Inc., began trading on Australia’s Securities Exchange (ASX:NYR) on Jan. 16, following an oversubscribed IPO that raised AU$8.5 million (US$5.8 million).
Boulder, Colo.-based startup Arpeggio Biosciences Inc. scooped up $3.2 million in seed funding in a round led by Khosla Ventures, with participation by Fundersclub, Fifty Years, TechU and Y Combinator.
HONG KONG – South Korean med tech Olive Healthcare Inc. has attracted ₩8 billion (US$6.91 million) in series B funding. The Seoul-based company is focused on abdominal fat scanning and breast cancer diagnosis, using nonradiative and noninvasive near infrared (NIR) technology, artificial intelligence (AI) algorithms, and big data processing for a customized medical service.